A PHASE 2 RANDOMIZED, MULTI-CENTER DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF THE V920 (RVSVG-ZEBOV-GP) EBOLA VIRUS VACCINE CANDIDATE IN HIV-INFECTED ADULTS AND ADOLESCENTS
- Registry ID
- CT14B (ACHIV-EBOLA)
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- CANADIAN IMMUNIZATION RESEARCH NETWORK (CIRN), DALHOUSIE UNIVERSITY
- Last update
- 2016-09-15
Conditions
- IMMUNIZATION
- HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Related clinical trials
- A PHASE 3, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CABOTEGRAVIR ULTRA LONG-ACTING PLUS RILPIVIRINE ULTRA LONG-ACTING OR CABOTEGRAVIR LONG-ACTING PLUS RILPIVIRINE LONG-ACTING IN ADULTS AND ADOLESCENTS WITH HIV WHO ARE VIROLOGICALLY SUPPRESSED ON ART
- A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF AN INJECTABLE REGIMEN OF GS-3242 IN COMBINATION WITH LENACAPAVIR VERSUS BIKTARVY (BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE) IN VIROLOGICALLY SUPPRESSED PEOPLE WITH HIV-1
- A PHASE 2B RANDOMIZED, OPEN-LABEL ACTIVE CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF ORAL VH4524184 COADMINISTERED WITH EMTRICITABINE AND TENOFOVIR ALAFENAMIDE IN TREATMENT NAÏVE VIREMIC PERSONS WITH HIV-1 (INNOVATE STUDY)
- A PHASE 2/3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL (PHASE 2) AND DOUBLE-BLIND (PHASE 3) STUDY TO EVALUATE THE ANTIRETROVIRAL ACTIVITY, SAFETY, AND TOLERABILITY OF ISLATRAVIR (ISL) AND ULONIVIRINE (ULO) ONCE WEEKLY COMPARED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (BIC/FTC/TAF) ONCE DAILY IN TREATMENT-NAÏVE ADULT PARTICIPANTS LIVING WITH HIV-1.
- A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULTICENTER,
SUPERIORITY STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF INJECTABLE CAB
LA + RPV LA IN VIREMIC PARTICIPANTS LIVING WITH HIV-1 (CROWN)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE A SWITCH TO AN ORAL WEEKLY ISLATRAVIR/LENACAPAVIR REGIMEN IN PEOPLE WITH HIV-1 WHO ARE VIROLOGICALLY SUPPRESSED ON BICTEGRAVIR/EMTRICITABINE/TENOFOVIR (B/F/TAF)
View on source registry